Cipla today announced its partnership with, Eli Lilly and Company (India), a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly's BASAGLAR (insulin glargine injection) in India. Under this agreement, Lilly’s BASAGLAR that is manufactured by Lilly will be marketed and distributed in India by Cipla.

Umang Vohra, MD & Global CEO, Cipla, said, ''Diabetes continues to be a focus area for Cipla and with the launch of strong brand like BASAGLAR, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables. Cipla’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication.''

Shares of the company gained Rs 11.45, or 2.12%, to trade at Rs 551.70. The total volume of shares traded was 104,214 at the BSE (1.01 p.m., Friday).